Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Bristol-Myers Squibb (BMS)

Status

Enrolling

Conditions

Non-small Cell Lung Cancer (NSCLC)

Treatments

Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies

Study type

Observational

Funder types

Industry

Identifiers

NCT06448793

CA209-1384

Details and patient eligibility

About

The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting

Enrollment

55 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients

Aged ≥18 years at the time of enrollment in the study
Resident of the US, Germany, or Japan
Able to read, speak, and understand English, German or Japanese
Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)

Physicians

Resident of the US, Germany, or Japan
Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology
Treated at least three new patients with resectable NSCLC in the past year

Exclusion criteria

Patients

Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
Being diagnosed with another malignancy alongside NSCLC
Not willing to be audio-recorded during the interview

Physicians

Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)
Not willing to be audio-recorded during the interview